MGMT and glioblastoma: In GBM patients, the survival analysis revealed a significantly longer median survival time in TC/CC variant genotype carriers compared to wild type patients, regardless of the post-surgical treatment and more evidently, after TMZ-based RT-CHT, both in MGMT methylated and unmethylated cases.